α1-antitrypsin deficiency and the hepatocytes - an elegans solution to drug discovery

Int J Biochem Cell Biol. 2014 Feb:47:109-12. doi: 10.1016/j.biocel.2013.12.006. Epub 2013 Dec 17.

Abstract

Hepatocytes are metabolically active cells of the liver that play an important role in the biosynthesis of proteins including α1-antitrypsin. Mutations in the α1-antitrypsin gene can lead to protein misfolding, polymerization/aggregation and retention of protein within the endoplasmic reticulum of hepatocytes. The intracellular accumulation of α1-antitrypsin aggregates can lead to liver disease and increased likelihood of developing hepatocellular carcinomas. Of note, only ~10% of individuals with α1-antitrypsin-deficiency develop severe liver disease suggesting that there are other genetic and/or environmental factors that determine disease outcome. The nematode, Caenorhabditis elegans, is a powerful genetic model organism to study molecular aspects of human disease. In this review, we discuss the functional similarities between the intestinal cells of C. elegans and human hepatocytes and how a C. elegans model of α1-antitrypsin-deficiency can be used as a tool for identifying genetic modifiers and small molecule drugs.

Keywords: C. elegans; Hepatocyte; Liver disease; Protein aggregation; α1-Antitrypsin deficiency.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Caenorhabditis elegans*
  • Disease Models, Animal*
  • Drug Discovery
  • Hepatocytes / metabolism
  • Hepatocytes / pathology*
  • Humans
  • alpha 1-Antitrypsin Deficiency / drug therapy*
  • alpha 1-Antitrypsin Deficiency / metabolism
  • alpha 1-Antitrypsin Deficiency / pathology*